Lateral Flow Conjugates
Lateral flow devices (LFDs) remain one of the most popular formats for point-of-care diagnostic testing, typically employing classical immunoassay architecture in the test designs.
​
Fleet Bioprocessing Ltd. can develop and manufacture the conjugates needed for an LFD application. Depending on the readout format, gold, latex particle or fluorescent labelling may be required for the detection conjugates.
​
Especially for LFDs for small molecules, it may also be necessary to prepare coating conjugates, in which the small molecule is conjugated to a carrier protein to enable it to be immobilised onto the membrane.
​
Fleet can help you with all these applications - contact us via our enquiry form here to discuss your lateral flow conjugate requirements.
Example Projects
Hapten conjugates for lateral flow assays
​
For small-molecule ("hapten") assays on a lateral flow format, it is often necessary to couple the hapten to a carrier protein to enable it to be bound to the membrane. Fleet has a long and successful history of preparing such conjugates for major players in the lateral flow field, and frequently carry out routine GMP supply to support long-term manufacturing. A UK-based point-of-care diagnostics company has recently adopted Fleet's conjugates for routine use after multiple batches showed good performance in their assay.
​
Fluorescent lateral flow conjugates for Dutch-led collaboration
​
The EC-funded PreventIt project aimed to develop lateral flow tests for infectious diseases, to be used perinatally in developing countries to reduce the risk of neonatal infection. Fleet used its expertise to formulate hard-to-target glycoprotein - fluorophore conjugates for use in high-sensitivity fluorescent LFD formats.
​
Hormone conjugates for Global diagnostics company's lateral flow assay
Fleet had been making a hormone-protein conjugate following a well-established method that they themselves had developed and with the customer had validated; multiple batches were made over the course of >5 years. Recently, a failed batch of material caused Fleet to investigate; proactively they worked to isolate the failure to an unforeseen raw material issue. At the same time, Fleet took the opportunity to redevelop the method to improve the sensitivity of the assay and reduce the amount of critical reagents required per batch.
​